SIPP INDUSTRIES INC NEW - SIPC STOCK NEWS

SIPP Industries (OTC PINK:SIPC), a multifaceted in the cannabis industry, has announced its quarterly plans and projections. Key highlights include:

1. Collaboration with Calypso Pharmaceuticals on AVEINA Melanoma topical, using 1000mg Nano Emulsified CBD and Peptide P16 to reduce Melanoma cell growth.

2. Development of innovative cGMP product formulations using nanotechnology for high bioavailability in various delivery formats.

3. Plans to expand into four additional U.S. markets by Spring 2025.

4. Relocation of headquarters to Dallas, Texas, and active search for a CFO to strengthen the executive team.

These initiatives aim to position SIPP Industries at the forefront of cannabinoid innovation and expand its presence in the cannabis community.

SIPP Industries (OTC: SIPC) has appointed Adam Graziano as its new CEO, effective immediately. Graziano brings over 20 years of business leadership and more than three decades in the insurance industry, managing a $500 million portfolio. Jakob Jorgensen, the former CEO, will remain as a business consultant and join Calypso Pharmaceuticals as their new CEO. This move aims to advance a research and development agreement between SIPP Industries and Calypso Pharmaceuticals to develop a topical treatment for melanoma using Peptide P16. The collaboration will also explore other peptides to address conditions like obesity, anxiety, and Alzheimer's disease. Graziano expressed his enthusiasm for leading SIPP Industries towards continued innovation and growth in the cannabis sector.

The company remains focused on developing and distributing high-quality cannabis products and pursuing innovative R&D initiatives.

SIPP Industries (OTC: SIPC) announced a Research and Development agreement with Calypso Pharmaceuticals to create a nano-emulsified topical formulation targeting melanoma. This collaboration, involving SIPP’s brand AVEINA, leverages Peptide P16, known for selectively killing melanoma cells. The nano-emulsification process by Calypso enhances drug solubility and stability, achieving over 95% bioavailability and minimizing systemic toxicity. This innovative method aims to improve the therapeutic index and reduce side effects. The global peptide therapeutics market, valued at $32.4 billion in 2023, is projected to grow at a CAGR of 7.4% from 2024 to 2030. The peptide cancer vaccine market, including melanoma treatments, was valued at $9.62 billion in 2022 and is expected to grow robustly. The initiative focuses on rigorous testing and clinical trials to validate the product's safety and efficacy.

Sipp Industries, Inc. (OTC: SIPC) acquires revenue share in Calypso Pharmaceuticals, a Texas-based company known for innovative cannabis and hemp products. Calypso's proprietary technology provides a 95% bioavailability, positioning them as industry leaders. The acquisition aims to enhance product development and market presence, aligning with the booming cannabis market expected to reach $444.3 billion by 2030.

Sipp Industries, Inc. (OTC: SIPC) announces a distribution agreement with SinuSave® for its SinuSave® CBD Nasal Spray products. The nasal spray, containing CBD and a patented composition of essential oils, is designed to provide relief from pain and symptoms associated with allergies, colds, and sinusitis. The partnership aims to offer innovative health solutions to consumers, with SIPP Industries responsible for sales, marketing, and distribution. The global nasal spray market is valued at $24.5 billion and expected to grow at a CAGR of 6.7%.

Sipp Industries (OTC Pink: SIPC) announces its initial order for newly launched Delta-8 infused sauces, featuring flavors like BBQ and Chipotle, with 1,000mgs of D8 per bottle. Following a favorable ruling by a California court on the legality of D8 THC under the 2018 Farm Bill, Sipp Industries has successfully integrated nano technology in its products. The company will co-sponsor a tasting event with Uncle Stu’s in Chicago to promote its innovative sauces and engage the local community, enhancing product awareness.

Sipp Industries (OTC Pink: SIPC) announced the successful fulfillment of orders for its cannabis products in partnership with Nectar Ventures. The company launched a new line of Delta-8 infused sauces named Sauz, featuring flavors like BBQ, Chipotle, and Siracha, with a production run of Major Hemp D8 drinks planned for the south-central states. Additionally, the firm debuted THC-infused pain lotion under the Aveina brand, exclusive to Oklahoma dispensaries. CEO Jakob Jorgensen emphasized their commitment to enhancing product quality and expanding distribution networks.

Sipp Industries (OTC Pink: SIPC) has secured its first order for the newly developed THC Nano-Infused Body Lotion, branded as Aveina, to be distributed through Argent Cannabis in Oklahoma. This medicinal lotion aims to provide pain relief and has a high bioavailability of 95% THC. Aveina will be available in 4 oz sizes containing 500mg of Nano THC by the end of May 2022. The partnership with one of Oklahoma's largest cannabis distributors positions Sipp Industries for significant growth in the state's emerging cannabis market.

Sipp Industries (OTC Pink: SIPC) announced its partnership with Nirvana Wholesale to distribute a new line of Delta-8 infused beverages under the Major Hemp brand, launching on April 20, 2022. The initial distribution will target over 100 vape and smoke shops in the Houston area, with plans for expansion throughout Texas. The Major Hemp Delta-8 beverages come in 16oz bottles containing 100mg of Delta-8, offering improved bioavailability. The global tea market is projected to increase from $200 billion in 2020 to $318 billion by 2025, positioning Sipp Industries for potential growth.